194 related articles for article (PubMed ID: 29899826)
1. Synthetic lethality in
Noack S; Raab M; Matthess Y; Sanhaji M; Krämer A; Győrffy B; Kaderali L; El-Balat A; Becker S; Strebhardt K
Oncotarget; 2018 May; 9(40):25842-25859. PubMed ID: 29899826
[TBL] [Abstract][Full Text] [Related]
2. Identification of synthetic lethality of PLK1 inhibition and microtubule-destabilizing drugs.
Hugle M; Belz K; Fulda S
Cell Death Differ; 2015 Dec; 22(12):1946-56. PubMed ID: 26024389
[TBL] [Abstract][Full Text] [Related]
3. Boosting the apoptotic response of high-grade serous ovarian cancers with CCNE1 amplification to paclitaxel in vitro by targeting APC/C and the pro-survival protein MCL-1.
Raab M; Kobayashi NF; Becker S; Kurunci-Csacsko E; Krämer A; Strebhardt K; Sanhaji M
Int J Cancer; 2020 Feb; 146(4):1086-1098. PubMed ID: 31286496
[TBL] [Abstract][Full Text] [Related]
4. Blocking Mitotic Exit of Ovarian Cancer Cells by Pharmaceutical Inhibition of the Anaphase-Promoting Complex Reduces Chromosomal Instability.
Raab M; Sanhaji M; Zhou S; Rödel F; El-Balat A; Becker S; Strebhardt K
Neoplasia; 2019 Apr; 21(4):363-375. PubMed ID: 30851646
[TBL] [Abstract][Full Text] [Related]
5. Eribulin synergizes with Polo-like kinase 1 inhibitors to induce apoptosis in rhabdomyosarcoma.
Stehle A; Hugle M; Fulda S
Cancer Lett; 2015 Aug; 365(1):37-46. PubMed ID: 25917079
[TBL] [Abstract][Full Text] [Related]
6. BI6727 and GSK461364A, potent PLK1 inhibitors induce G2/M arrest and apoptosis against cholangiocarcinoma cell lines.
Riantana H; Waenphimai O; Mahalapbutr P; Karnchanapandh K; Vaeteewoottacharn K; Wongkham S; Sawanyawisuth K
Pathol Res Pract; 2023 Aug; 248():154678. PubMed ID: 37454493
[TBL] [Abstract][Full Text] [Related]
7. CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes.
Petersen S; Wilson AJ; Hirst J; Roby KF; Fadare O; Crispens MA; Beeghly-Fadiel A; Khabele D
Gynecol Oncol; 2020 May; 157(2):405-410. PubMed ID: 32044108
[TBL] [Abstract][Full Text] [Related]
8. A Synthetic Dosage Lethal Genetic Interaction Between CKS1B and PLK1 Is Conserved in Yeast and Human Cancer Cells.
Reid RJ; Du X; Sunjevaric I; Rayannavar V; Dittmar J; Bryant E; Maurer M; Rothstein R
Genetics; 2016 Oct; 204(2):807-819. PubMed ID: 27558135
[TBL] [Abstract][Full Text] [Related]
9. Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition.
Au-Yeung G; Lang F; Azar WJ; Mitchell C; Jarman KE; Lackovic K; Aziz D; Cullinane C; Pearson RB; Mileshkin L; Rischin D; Karst AM; Drapkin R; Etemadmoghadam D; Bowtell DD
Clin Cancer Res; 2017 Apr; 23(7):1862-1874. PubMed ID: 27663592
[No Abstract] [Full Text] [Related]
10. Synergistic induction of apoptosis by a polo-like kinase 1 inhibitor and microtubule-interfering drugs in Ewing sarcoma cells.
Weiß LM; Hugle M; Romero S; Fulda S
Int J Cancer; 2016 Jan; 138(2):497-506. PubMed ID: 26260582
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo.
Spänkuch B; Heim S; Kurunci-Csacsko E; Lindenau C; Yuan J; Kaufmann M; Strebhardt K
Cancer Res; 2006 Jun; 66(11):5836-46. PubMed ID: 16740723
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic mechanism of PLK1 inhibitor GSK461364 against osteosarcoma: Mitotic arrest, apoptosis, cellular senescence, and synergistic effect with paclitaxel.
Chou YS; Yen CC; Chen WM; Lin YC; Wen YS; Ke WT; Wang JY; Liu CY; Yang MH; Chen TH; Liu CL
Int J Oncol; 2016 Mar; 48(3):1187-94. PubMed ID: 26794530
[TBL] [Abstract][Full Text] [Related]
13. Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer.
Etemadmoghadam D; Au-Yeung G; Wall M; Mitchell C; Kansara M; Loehrer E; Batzios C; George J; Ftouni S; Weir BA; Carter S; Gresshoff I; Mileshkin L; Rischin D; Hahn WC; Waring PM; Getz G; Cullinane C; Campbell LJ; Bowtell DD
Clin Cancer Res; 2013 Nov; 19(21):5960-71. PubMed ID: 24004674
[TBL] [Abstract][Full Text] [Related]
14. Targeting Polo-like kinase 1 in SMARCB1 deleted atypical teratoid rhabdoid tumor.
Alimova I; Pierce AM; Harris P; Donson A; Birks DK; Prince E; Balakrishnan I; Foreman NK; Kool M; Hoffman L; Venkataraman S; Vibhakar R
Oncotarget; 2017 Nov; 8(57):97290-97303. PubMed ID: 29228610
[TBL] [Abstract][Full Text] [Related]
15. PLK1 inhibition leads to mitotic arrest and triggers apoptosis in cholangiocarcinoma cells.
Moolmuang B; Chaisaingmongkol J; Singhirunnusorn P; Ruchirawat M
Oncol Lett; 2024 Jul; 28(1):316. PubMed ID: 38807667
[TBL] [Abstract][Full Text] [Related]
16. CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition.
Gallo D; Young JTF; Fourtounis J; Martino G; Álvarez-Quilón A; Bernier C; Duffy NM; Papp R; Roulston A; Stocco R; Szychowski J; Veloso A; Alam H; Baruah PS; Fortin AB; Bowlan J; Chaudhary N; Desjardins J; Dietrich E; Fournier S; Fugère-Desjardins C; Goullet de Rugy T; Leclaire ME; Liu B; Bhaskaran V; Mamane Y; Melo H; Nicolas O; Singhania A; Szilard RK; Tkáč J; Yin SY; Morris SJ; Zinda M; Marshall CG; Durocher D
Nature; 2022 Apr; 604(7907):749-756. PubMed ID: 35444283
[TBL] [Abstract][Full Text] [Related]
17. CCNE1 is a potential target of Metformin for tumor suppression of ovarian high-grade serous carcinoma.
Mei J; Tian H; Huang HS; Wu N; Liou YL; Chu TY; Wang J; Zhang W
Cell Cycle; 2023 Jan; 22(1):85-99. PubMed ID: 36004387
[TBL] [Abstract][Full Text] [Related]
18. Targeting Therapeutic Resistance and Multinucleate Giant Cells in CCNE1-Amplified HR-Proficient Ovarian Cancer.
Bai S; Taylor SE; Jamalruddin MA; McGonigal S; Grimley E; Yang D; Bernstein KA; Buckanovich RJ
Mol Cancer Ther; 2022 Sep; 21(9):1473-1484. PubMed ID: 35732503
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.
Menendez JA; Vellon L; Colomer R; Lupu R
Int J Cancer; 2005 May; 115(1):19-35. PubMed ID: 15657900
[TBL] [Abstract][Full Text] [Related]
20. Bcl-2 degradation is an additional pro-apoptotic effect of polo-like kinase inhibition in cholangiocarcinoma cells.
Sydor S; Jafoui S; Wingerter L; Swoboda S; Mertens JC; Gerken G; Canbay A; Paul A; Fingas CD
World J Gastroenterol; 2017 Jun; 23(22):4007-4015. PubMed ID: 28652654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
